LLY
Eli Lilly and Company
LLY has the edge over SYK overall, supported by stronger fundamentals and stronger modeled upside.
SYK
Stryker Corporation
SYK has lower modeled downside risk, despite its lower overall score.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
SYK Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Strong | |
| Healthy |
SYK's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
SYK PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 20x | $312 | — |
| Current | 33x | $312 | — |
| Cheap | 37x | $344 | +10% |
| Fair | 43x | $402 | +29% |
| Expensive | 51x | $480 | +54% |
Historical ranges are pointers, not guarantees.
SYK has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over SYK on the outlook, with more favorable profitability expectations.
SYK Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Stable | |
| Moderate | |
| Moderate |
Analysts expect earnings and revenue growth for SYK, with profitability holding steady.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over SYK on earnings, with more consistent year-over-year improvement.
SYK Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $15.99 | +70% |
| Q3 2026 | $9.39 | +23% |
| Q2 2026 | $9.65 | +28% |
| Q1 2026 | $8.64 | +17% |
| Q4 2025 | $8.40 | +8.2% |
| Q3 2025 | $7.61 | -18% |
| Q2 2025 | $7.55 | -16% |
| Q1 2025 | $7.40 | -16% |
| Q4 2024 | $7.76 | -5.9% |
SYK earned $9.39 per share over the past year, up 23% from the year before.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over SYK on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over SYK on profitability, with a higher operating margin.
SYK Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $6.5B | +7.6% |
| Q2 2026 | $6.6B | +9.4% |
| Q1 2026 | $6B | +2.6% |
| Q4 2025 | $7.2B | +11% |
| Q3 2025 | $6.1B | +10% |
| Q2 2025 | $6B | +11% |
| Q1 2025 | $5.9B | +12% |
| Q4 2024 | $6.4B | +11% |
SYK's revenue has grown year over year every quarter since late 2020: $6.5B last quarter, up 7.6% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 16% | -2.9 points |
| Q2 2026 | 25% | +6.7 points |
| Q1 2026 | 16% | +1.3 points |
| Q4 2025 | 25% | +16 points |
| Q3 2025 | 19% | -1 points |
| Q2 2025 | 18% | -0.9 points |
| Q1 2025 | 14% | -4.3 points |
| Q4 2024 | 9% | -13 points |
SYK's operating margin was 16% last quarter, down 2.9 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
SYK Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.2B | -9.5% |
| Q2 2026 | $1.1B | +14% |
| Q1 2026 | $415M | +227% |
| Q4 2025 | $1.9B | +13% |
| Q3 2025 | $1.4B | +3.8% |
| Q2 2025 | $928M | +93% |
| Q1 2025 | $127M | +243% |
| Q4 2024 | $1.7B | +20% |
SYK has the edge over LLY on cash flow, with more consistent year-over-year improvement.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over SYK on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
SYK Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -1.3M shares |
| 1 year | -0.5% | -2M shares |
| 3 years | +0.2% | +700K shares |
| 5 years | +0.5% | +2M shares |
| Available history | +1.3% | +4.8M shares |
SYK has 385M diluted shares, down 0.5% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY has the edge over SYK on leverage, with a lower net debt burden relative to earnings.
SYK Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.6x | Healthy |
| Q1 2026 | 1.8x | Healthy |
| Q4 2025 | 1.8x | Healthy |
| Q3 2025 | 2.6x | Moderate |
| Q2 2025 | 2.9x | Moderate |
| Q1 2025 | 3.1x | Elevated |
| Q4 2024 | 2.1x | Moderate |
SYK's net debt is about 1.6 years of its operating earnings (EBITDA), down from 2.6 years a year ago.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
SYK Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 50.4 | Neutral |
| Stochastic | 51.7 | Neutral |
SYK's weekly RSI is 50 (neutral) and its Stochastic is 52 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
SYK PE vs Healthcare Sector
| Metric | SYK | Sector median | Relative |
|---|---|---|---|
| PE | 33x | 26x | 29% above |
| PE % | 9 | 29 | 20 pts below |
SYK has the edge over LLY on valuation relative to its sector.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over SYK on trend strength, trading above more of its moving averages.
SYK Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $294.6 | 6% above |
| 20 week MA | $309.1 | 1.1% above |
| 50 week MA | $327.6 | 4.6% below |
| 100 week MA | $352.1 | 11% below |
| 200 week MA | $333.6 | 6.4% below |
SYK has bounced recently, but its long-term trend is still down: it's above its 8- and 20-week averages, but 6.4% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over SYK on returns for 2026, with the stronger performance.
SYK Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $210.6 | $237.1 | +13% |
| 2021 | $237.1 | $268.3 | +13% |
| 2022 | $268.3 | $242.8 | -9.5% |
| 2023 | $242.8 | $299.5 | +23% |
| 2024 | $299.5 | $367.1 | +23% |
| 2025 | $367.1 | $354.2 | -3.5% |
| 2026 YTD | $354.2 | $312.4 | -12% |
SYK has finished higher in four of the last six years. It's down 12% so far in 2026.